UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 28, 2022

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-35547 (Commission File Number) 36-4392754 (IRS Employer Identification No.)

222 Merchandise Mart Chicago, Illinois (Address of Principal Executive Offices)

60654 (Zip Code)

Registrant's Telephone Number, Including Area Code: 800 334-8534

	(Former Nat	me or Former Address, if Changed	Since Last Report)	
Che	eck the appropriate box below if the Form 8-K filing is intended to sir	multaneously satisfy the fili	ng obligation of the registrant under any of the following provisions:	
	Written communications pursuant to Rule 425 under the Securities	Act (17 CFR 230.425)		
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act	t (17 CFR 240.14a-12)		
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))			
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			
	Securities reg	gistered pursuant to Section	on 12(b) of the Act:	
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered	
	Common Stock, par value \$0.01 per share	MDRX	NASDAQ Global Select Market	
	icate by check mark whether the registrant is an emerging growth con Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).	mpany as defined in Rule 40	05 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of	
Em	nerging growth company			
	in emerging growth company, indicate by check mark if the registrant ounting standards provided pursuant to Section 13(a) of the Exchange		xtended transition period for complying with any new or revised financial	

Item 7.01 Regulation FD Disclosure.

On September 28, 2022, the Company will host a virtual Investor Day. A copy of the Company's presentation is furnished as Exhibit 99.1. The Company intends to use this presentation at other investor conferences.

The information furnished pursuant to this Item shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Exhibit Description	
99.1	Copy of Allscripts Healthcare Solutions, Inc. presentation slides	
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Date: September 28, 2022

/s/ Eric Jacobson

Eric Jacobson Senior Vice President, Deputy General Counsel and Corporate Secretary





Investor Day

Allscripts/Veradigm

September 28, 2022



Allscripts Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as "future," "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "will," "would," "could," "can," "may," "look forward," "pipeline" and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance or events.

Certain factors that could cause our actual results to differ materially from those described in the forward-looking statements include, but are not limited to: our use of the proceeds from the sale of our Hospitals and Large Physician Practices Business; our ability to achieve the margin targets associated with our profitability initiatives within the contemplated time periods, if at all; the continued impact of the COVID-19 pandemic; security breaches resulting in unauthorized access to our or our clients computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; the failure by Practice Fusion to comply with the terms of the settlement agreements with the U.S. Department of Justice (the "DOJ"); the costs and burdens of compliance by Practice Fusion with the terms of its settlement agreements with the DOJ; additional investigations and proceedings from governmental entities or third parties other than the DOJ related to the same or similar conduct underlying the DOJ's investigations into Practice Fusion's business practices; our ability to recover from third parties (including insurers) any amounts paid in connection with Practice Fusion's settlement agreements with the DOJ and related inquiries; the expected financial results of businesses acquired by us; the successful integration of businesses acquired by us; the anticipated and unanticipated expenses and liabilities related to businesses acquired by us, including the civil investigation by the U.S. Attorney's Office involving our Enterprise Information Solutions business; other risks associated with investments and acquisitions; risks associated with disposition of the Hospitals and Large Physicians Practices Business, our failure to compete successfully; consolidation in our industry; current and future laws, regulations and industry initiatives; increased government involvement in our industry; the failure of markets in which we operate to develop as quickly as expected; our or our customers' failure to see the benefits of government programs; changes in interoperability or other regulatory standards; our ability to maintain and expand our business with existing clients or effectively transition clients to newer products; the effects of the realignment of our sales, services and support organizations; market acceptance of our products and services; the unpredictability of the sales and implementation cycles for our products and services; our ability to manage future growth; our ability to introduce new products and services; our ability to establish and maintain strategic relationships; risks associated with investments and acquisitions; the performance of our products; our ability to protect our intellectual property rights; the outcome of legal proceedings involving us; our ability to hire, retain and motivate key personnel; performance by our content and service providers; liability for use of content; price reductions; our ability to license and integrate third-party technologies; risks related to global operations; variability of our quarterly operating results; risks related to our outstanding indebtedness; changes in tax rates or laws; business disruptions; our ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting our business is contained in our filings with the Securities and Exchange Commission, including under the caption "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Qs. We do not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in our business, financial condition or operating results over time.





Agenda Introduction **Rick Poulton** CHIEF EXECUTIVE OFFICER Tom Langan PRESIDENT & CHIEF COMMERCIAL OFFICER **Veradigm Value Provider Base Foundation** Jonathan Malek SVP & GM, PROVIDER Jay Bhattacharyya Payer Connectivity SVP & GM, PAYER **New Perspectives for** Stuart Green SVP & GM, LIFE SCIENCE Biopharma **Leah Jones Financial Update**

CHIEF FINANCIAL OFFICER



Veradigm and the Veradigm Network are *different* because of our connectivity, scale, and expertise which provides a uniquely comprehensive scope and depth of interconnected resources, so our clients can drive improved health outcomes for the patients they serve.



Veradigm Value

Tom Langan President & Chief Commercial Officer



Growth Leaders



EXPERIENCE Executive Leadership, Commercial, and Sales Positions













Bhattacharyya SVP & GM PAYER









Stuart Green SVP & GM LIFE SCIENCE













EXPERIENCE Leadership Positions in Technology, Product & Operations









VP



EXPERIENCE Leadership Positions in Marketing, Sales & Operations









Bruce Lucarelli

VP & CHIEF DATA OFFICER









Market Trends Accelerate Our Growth Strategy



MOVE TO OUTPATIENT AND AMBULATORY CARE



INCREASE IN HEALTHCARE SPENDING



CHANGING INTEROPERABILITY STANDARDS



INCREASED NEED FOR HEALTH ECONOMICS & OUTCOMES RESEARCH



EXPANDING USE OF REAL-WORLD DATA



DYNAMIC REGULATORY ENVIRONMENT



GROWTH STRATEGY

Leverage Convergence of Healthcare Market and the Transition to Value-Based Care



Grow Provider Network

Expand Data Sources

Increase Share of Wallet





Veradigm Journey Starts with the Provider Footprint

PROVIDER VALUE PROPOSITION



2 EHRs Targeted at Different Tiers of Practice Complexity Partner with
Over 330K
Healthcare
Providers
via the
Veradigm
Network

Industryleading Practice Management / Clearinghouse Solution Enable the transition to Value Based Care


Virtual Care Enablement / Patient Engagement



Revenue Cycle Management Services



The Veradigm Formula



Veradigm Network Growth Model

Veradigm Network Value = COLLECTIVE SCALE + DATA + WORKFLOW CONNECTIVITY





Competitive Market Landscape





Veradigm's Competitive Advantages



Patented Risk Adjustment Methodology with dynamic intervention planning empowers Payers to identify actionable interventions



Easy-to-use, intuitive Clinical, Financial, Revenue Cycle and Patient Engagement solutions designed for Independent Providers



Scalable access to Research and Real-World Clinical Data via direct connection with the Point-of-Care



Bi-directional clinical and financial data exchange between Payers and 200k+ Providers drives value for all stakeholders





Secure, Reliable, and Compliant Cloud Solutions that scale



Highly-targeted, scalable delivery of Biopharma Awareness Messaging to HCPs via their EHRs











The Provider Network = Veradigm Foundation



Focus our Growth Through Enabling the transition to Value Based Care 2 EHRs Targeted at Different Healthcare Industry-leading Clearinghouse **Provider Audiences** Solution¹ & Practice Management Revenue Cycle Management Virtual Care and Patient Engagement Services **Wallet Share Industry Consolidation**

1. <u>Veradigm Payerpath Ranked #1 by Blackbook in 2022</u> for Ambulatory Claims Management and Clearinghouse Solutions and End-To-End RCM Software Technology, Physicians Practices & Ambulatory Facilities/Groups Solutions



Veradigm Provider Solutions

EHR

- Cloud EHR serves over 21,000 small practices
- Professional EHR serves over 2,100 complex practices

Practice Mgmt. & Rev Cycle Mgmt.

- 850 healthcare services organizations
- \$100B processed charges
- Growth market among Cloud EHR practices

Patient Engagement

- Personal Health Record
 Patient Portal
- Telehealth, scheduling, payments and more
- Over 100M patient engagement users

Enterprise Platform

 1,000+ platform customers using commercial APIs for financial and clinical transactions




How Does Provider Power Veradigm?





Our Focus





A Foundation of Experience & Scale

Senior, experienced technology team behind the Cloud EHR Deep domain expertise across EHR and Practice Management, across decades

Proven, rapid and resilient execution capabilities


In 2021 alone...

1B+	Rev Cycle Transactions
1B+	Transactions Eligibility and medication history
953M+	Verifications/Transformations
600M+	ePrescriptions Including EPCS
400M+	Claims Transactions

300M	Messaging	
53M+	Labs & Imaging Electronic orders and results	
28M+	Real Time Benefit Inquiries Veradigm Community Direct Messaging	
10M+		
730K+	eAuthorizations	



Veradigm Network in Action










Payer Data & Analytics | Large Addressable Market

Veradigm Current \$3.3B Addressable Payer Data and Analytics Market Segment Expected to Grow 20%+ Annually







Our insightful solutions lead to better patient outcomes, increased revenue, and lower costs

Florida Blue 🚭 🗑 Children's **EmblemHealth** Anthem. United Healthcare PriorityHealth® Humana 30M+ 100+ health plan 9 of top 20 members across clients health plans the US Our Payer focused solutions connect to more than **275K Providers** across the US Solutions address Medicare Advantage, Managed Medicaid and ACA markets




Veradigm Payer-Provider Collaboration Platform

Simplifies Provider & Payer collaboration through analytics and better point-of-practice workflows





End to End Payer Solutions







Power of the Platform in a Scaled Network

Platform Scale enables Veradigm to engage providers and patients in a way that moves the needle for health plans nationwide



Gaps In Care intervention messaging to maximize Quality and Risk Adjustment program value

TOTAL PROVIDERS IN US: ~1.1 million

TOTAL VERADIGM PAYER FOCUSED CONNECTED PROVIDERS*: ~275,000 (~25% of the country)

TOTAL VERADIGM HEALTH PLAN CUSTOMERS: 100+

VERADIGM PERFORMS ANALYTICS & SERVICES ON: 30M+ covered lives

*comprised of EHRs and EDI Clearinghouse doesn't represent the entire Veradigm Network



The Impact of One End-to-End Solution

Observed Results from Current Clients





Growth Initiatives

Net New Health Plan relationships White space
Cross-sell/
Up-sell


Expand Provider network

Organic EHR provider growth

EHR Partnerships: Long Tail Expand Provider engagement capabilities

Introduce New Patient/Member engagement capabilities









OVERVIEW

図 Veradigm Life Science

Leverage Real-world Practice Data to Generate Insights

What does our Life Science business do and who do we serve?

Provide
data and
registry
information
(ACC) as
standalone or
combined data
sets

We perform registry and study implementation services via our RWE Consulting group

Digital Health
Media serves
agencies and
direct sponsors
by providing
ads via our
Provider
platforms



Rich Real-World Data at the Point-of-Care

Veradigm Ambulatory EHR Database

One of the largest deidentified EHR datasets

Derived from Veradigm Network ambulatory EHRs:

Professional Touchworks

Practice NextGen

Extensive nationally distributed patient population from a wide range of practice sizes Supports patient longitudinal analysis, stand-alone or linked to other real-world data sources




Fusion





Veradigm Real-World Data Defined





Reach Providers at the Point-of-Care



- Position marketing messages during the healthcare provider EHR workflow in a compliant manner
- Drive awareness and adherence
- Enhance return on advertising dollars by (3) delivering promotional messaging with reach and precise targeting

*The Practice Fusion EHR displays advertisements in an iframe window that is separate and distinguishable from the clinical and practice management workflow within the EHR. No biopharma or device advertisements appear during the prescribing workflow consistent with applicable law



EHR Leader in Digital Media – Point of Care Messaging

20B+

Ad impressions served since 2011

100+

Biopharma companies working with Veradigm for point-of-care media 11+

Years delivering multi-platform point-of-care media 1K+

Campaigns successfully executed over 11 years



Moderna Real-World Evidence

Evaluating Vaccine Effectiveness

Situation

Designing and implementing an FDAmandated safety program

Approach

Leverage the Veradigm Cardiovascular Registry, as well as the Practice Fusion EHR

Facilitating research studies

Outcomes



Use of our EHR data assets with broad publicly available data to provide insight



Enabling and empowering Moderna to conduct internal analyses with data assets



Veradigm has been a valuable resource to Moderna by helping us gain insight into vaccination rates, so we can continue to help protect vulnerable populations from COVID-19.

James Mansi

VP MEDICAL AFFAIRS, NORTH AMERICA | MODERNA





Financial Update Leah Jones, Chief Financial Officer



Veradigm Revenue Performance







Veradigm Margin Performance





¹ See reconciliation of non-GAAP metrics in the appendix of this presentation.



Veradigm Provider





¹ See reconciliation of non-GAAP metrics in the appendix of this presentation.

Growth Levers

- New Client Wins
- Expand Wallet Share
- Value-Based Care Partnerships
- Market Consolidation

39

Conversely 02022 Veradian® LAE rights reserve

Veradigm Payer & Life Science





¹ See reconciliation of non-GAAP metrics in the appendix of this presentation.

Growth Levers

- Expand Data Sources
- Broaden Existing Partnerships
- Increase Media Footprint
- Grow Health Plan Partnerships



Allscripts | Free Cash Flow % of Revenue Accelerate




¹ See reconciliation of non-GAAP metrics in the appendix of this presentation.



Allscripts | Simultaneously Reducing Share Count & Leverage





¹ See reconciliation of non-GAAP metrics in the appendix of this presentation.



Allscripts 2022 Guidance Reaffirmed

6% - 7%

Veradigm Revenue Growth YOY

10% - 15%

Veradigm Adjusted EBITDA Growth YOY

\$110M - \$120M

Allscripts Free Cash Flow



Closing Comments Rick Poulton Chief Executive Officer







Converient @2022 Varadion® LAE rights reserve.



Appendix: Non-GAAP Reconciliations



Allscripts Non-GAAP Segment Reconciliation (Veradigm Segment)

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information Reconciliation - Segment Details

(In millions) (unaudited)

Total Veradigm

Revenue, as reported

Gross profit, GAAP

Acquisition-related amortization

Stock-based compensation expense

Non-GAAP Gross profit

Income (loss) from operations, GAAP

Acquisit ion-related amortization

Stock-based compensation expense

Transaction and other

Non-GAAP Income (loss) from operations

Asset Impairment Charges

Adjusted EBITDA

Depreciation	and	amortizatio

		2021		27
Q1	Q2	Q3	Q4	Total
\$126.4	\$133.4	\$137.2	\$155.2	\$552.2
\$58.6	\$63.6	\$65.7	\$84.6	\$272.5
1.8	1.8	1.7	1.8	7.1
0.3	0.3	0.3	0.3	1.2
\$60.7	\$65.7	\$67.7	\$86.7	\$280.8
\$11.4	\$17.9	\$16.9	\$35.2	\$81.4
4.2	4.2	4.1	3.9	16.4
3.4	3.1	3.2	3.3	13.0
0.0	0.0	0.0	0.0	0.0
\$19.0	\$25.2	\$24.2	\$42.4	\$110.8
0.0	0.2	0.6	0.0	0.8
9.4	9.9	9.7	9.5	38.5
\$28.4	\$35.3	\$34.5	\$51.9	\$150.1

	2022	
Q1	Q2	Total
\$136.3	\$144.6	\$280.9
\$69.2	\$75.4	\$144.6
1.6	1.7	3.3
0.3	0.3	0.6
\$71.1	\$77.4	\$148.5
\$18.1	\$24.0	\$42.1
3.8	4.0	7.8
3.6	2.3	5.9
0.0	0.0	0.0
\$25.5	\$30.3	\$55.8
0.0	0.0	0.0
9.7	9.5	19.2
\$35.2	\$39.8	\$75.0



Allscripts Non-GAAP Segment Summary

Total Veradigm, Non-GAAP

Revenue Gross profit Gross margin Income from operations Adjusted EBITDA Adjusted EBITDA margin

		2021		
Q1	Q2	Q3	Q4	Total
126.4	133.4	137.2	155.2	552.2
60.7	65.7	67.7	86.7	280.8
48.0%	49.3%	49.3%	55.9%	50.9%
19.0	25.2	24.2	42.4	110.8
28.4	35.3	34.5	51.9	150.1
22.5%	26.5%	25.1%	33.4%	27.2%

	2022	
Q1	Q2	Total
136.3	144.6	280.9
71.1	77.4	148.5
52.2%	53.5%	52.9%
25.5	30.3	55.8
35.2	39.8	75.0
25.8%	27.5%	26.7%



Allscripts Non-GAAP Reconciliations (Provider and Payer & Life Sciences)

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information Reconciliation - Provider and Payer & Life Sciences Details

(In millions) (unaudited)

Veradigm Provider

Gross profit, as reported

Acquisition-related amortization Stock-based compensation expense

Non-GAAP Gross profit

Veradigm Payer & Life Sciences Gross profit, as reported

Acquisition-related amortization Stock-based compensation expense

Non-GAAP Gross profit

Total Veradigm

Gross profit, as reported

Acquisition-related amortization Stock-based compensation expense

Non-GAAP Gross profit

		2021				2022	
Q1	Q2	Q3	Q4	Total	Q1	Q2	Total
\$48.2	\$50.8	\$52.6	\$69.0	\$220.6	\$57.4	\$56.5	\$113.9
1.3	1.3	1.3	1.3	5.2	1.1	1.2	2.3
0.3	0.3	0.3	0.3	1.2	0.3	0.3	0.6
\$49.8	\$52.4	\$54.2	\$70.6	\$227.0	\$58.8	\$58.0	\$116.8
\$10.4	\$12.8	\$13.1	\$15.6	\$51.9	\$11.8	\$18.9	\$30.7
0.5	0.5	0.4	0.5	1.9	0.5	0.5	1.0
0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
\$10.9	\$13.3	\$13.5	\$16.1	\$53.8	\$12.3	\$19.4	\$31.7

\$58.6	\$63.6	\$65.7	\$84.6	\$272.5	\$69.2
1.8	1.8	1.7	1.8	17.1	1.6
0.3	0.3	0.3	0.3	1.2	0.3
\$60.7	\$65.7	\$67.7	\$86.7	\$280.8	\$71.1

\$69.2	\$75.4	\$144.6
1.6	1.7	3.3
0.3	0.3	0.6
\$71.1	\$77.4	\$148.5

2 49

Allscripts Non-GAAP Summary (Provider and Payer & Life Sciences)

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information from Continuing Operations - Provider and Payer and Life Sciences Details

(In millions) (unaudited)

Veradigm Provider, Non-GAAP

Revenue

Gross profit

Gross margin

Veradigm Payer & Life Sciences, Non-GAAP

Revenue Gross Profit

Gross Margin

Total Veradigm, Non-GAAP

Revenue Gross profit Gross margin

		2021		
Q1	Q2	Q3	Q4	Total
103.9	108.1	110.8	126.3	449.0
49.8	52.4	54.2	70.6	227.0
47.9%	48.5%	48.9%	55.9%	50.6%
22.5	25.3	26.5	28.9	103.2
10.9	13.3	13.5	16.1	53.8
48.4%	52.6%	50.9%	55.7%	52.1%
126.4	133.4	137.3	155.2	552.2
60.7	65.7	67.7	86.7	280.8
48.0%	49.3%	49.3%	55.9%	50.9%

	2022	
Q1	Q2	Total
112.3	112.6	224.9
58.8	58.0	116.8
52.4%	51.5%	51.9%
1201500	1/22/200	22/20
24.0	32.0	56.0
12.3	19.4	31.7
51.3%	60.6%	56.6%
136.3	144.6	280.9
71.1	77.4	148.5
52.2%	53 5%	52.9%



Allscripts Non-GAAP Reconciliations (Free Cash Flow & Free Cash Flow % of Revenue)

Allscripts Healthcare Solutions, Inc. Non-GAAP Financial Information - Free Cash Flow

(In millions) (Unaudited)

	Trailing Twelve Months			
	Q419	Q420	Q421	Q222
Net cash provided by (used in) operating activities - continuing operations Addback of DOJ settlement	\$15.4 0.0	\$12.3 147.2	\$248.3 0.0	\$199.8 0.0
Adjusted Net cash provided by (used in) operating activities - continuing operations	\$15.4	\$159.5	\$248.3	\$199.8
Cash flows from investing activities:				
Capital expenditures	(16.5)	(17.0)	(5.3)	(3.8)
Capitalized software	(103.3)	(88.0)	(73.3)	(56.1)
Free cash flow	(\$104.4)	\$54.5	\$169.7	\$139.9

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information - Free Cash Flow as % of Revenue

(In millions) (Unaudited)

	Trailing Twelve Months					
	Q419	Q420	Q421	Q222		
Free cash flow	(\$104.4)	\$54.5	\$169.7	\$139.9		
Revenue as reported, trailing twelve months	1,633	1,503	1,503	1,05.5		
Free cash flow as % trailing twelve months of severagen as reported	-69%	4%	11%	13%		



Allscripts Non-GAAP Reconciliations (Non-GAAP diluted shares outstanding)

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information - Weighted shared outstanding - diluted

	Three Months Ended December 31,	Three Months Ended December 31,	Three Months Ended December 31,	Three Months Ended June 30,	
	2019	2020	2021	2022	
Weighted shares outstanding - diluted	164.9	155.9	127.8	118.7	
Less the net effect of convertible notes and note hedges	0.0	0.0	-2.5	0.9	
Non-GAAP Weighted shares outstanding - diluted	164.9	155.9	125.3	119.6	

52

Allscripts | Non-GAAP Reconciliations (Net Leverage)

Allscripts Healthcare Solutions, Inc. Non-GAAP Financial Information - Net Leverage

(In millions) (Unaudited)

	Q4'19	Q4'20	Q4'21	Q2'22	
Total Debt	\$973.0	\$207.9	\$382.9	\$207.9	
Total Cash (Cash, Cash Equivalents, Restricted Cash)	137.5	537.5	190.5	501.5	
Total debt less total cash	\$835.5	(\$329.6)	\$192.4	(\$293.6)	
Trailing twelve months of adjusted EBITDA	\$295.1	\$311.9	\$301.1	\$166.7	
Net Leverage 1	2.8	-1.1	0.6	-1.8	

¹ Net Leverage: Total debt less total cash divided by trailing tweleve months of adjusted EBITDA

5

Allscripts Non-GAAP Reconciliations (Adjusted EBITDA)

Allscripts Healthcare Solutions, Inc. Non-GAAP Financial Information - Adjusted EBITDA

(In millions) (Unaudited)

	Trailing Twelve Months				*Trailing Six Month	
	Q4'19	Q4'20	Q4'21	*Q2'22'	Q4'21 1	Q2
Income (loss) from operations, as reported	(\$99.6)	(\$130.9)	\$84.4	\$61.1	\$59.9	
Plus:						
Depreciation and amortization	181.7	176.3	56.9	\$54.7	27.6	
Impairments	37.2	76.6	0.5	\$0.4	0.4	
Stock-based compensation expense	42.6	38.4	13.9	\$22.6	6.5	
Transaction and other	48.9	64.3	1100010	27.9	0.0	
Adjusted EBITDA from continuing operations	210.8	224.7	155.8	166.7	94.4	
Adjusted EBITDA related to businesses reported as discontinued operations	84.3	87.2	145.3	0.0	0.0	
Adjusted EBITDA	\$295.1	\$311.9	\$301.1	\$166.7	594.4	

¹Excludes Altera Adjusted EBITDA

54

Allscripts Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents non-GAAP bookings, gross profit, income from operations, Adjusted EBITDA, Adjusted EBITDA margin, and free cash flow, which are considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. The definitions of non-GAAP financial measures are presented below:

- Non-GAAP gross profit consists of GAAP gross profit, as reported, and excludes acquisition-related amortization and; stock-based compensation expense. Non-GAAP gross margin consists of non-GAAP gross profit as a percentage of revenue in the applicable period.
- Non-GAAP income from operations consists of GAAP income (loss) from operations, as reported, and excludes acquisition-related amortization; stock-based compensation expense; and transaction and other costs.
- Adjusted EBITDA is a non-GAAP measure and consists of GAAP income/(loss) from operations, as reported, and adjusts for: depreciation and amortization; asset impairment charges; stock-based compensation expense; and transaction and other costs.
- Adjusted EBITDA margin is a non-GAAP measure that is calculated by dividing Adjusted EBITDA by revenue.
- Non-GAAP diluted weighted shares outstanding consists of diluted weighted shares outstanding, as reported, less the dilutive impact
 of 0.875% convertible notes due to the intent to settle the principal in cash and shares to be delivered at settlement by the convertible
 note hedge.
- Free cash flow consists of GAAP cash flows from continuing operations in the applicable period, net of capital expenditures and
 capitalized software costs. Reconciliations to GAAP cash flows from continuing operations are found in Table 6 within this press
 release.
- Non-GAAP diluted weighted shares outstanding: consists of diluted weighted shares outstanding, as reported, less the dilutive impact
 of 0.875% convertible notes due to the intent to settle the principal in cash and shares to be delivered at settlement by the convertible
 note hedge.
- Net Leverage: Total debt less total cash divided by trailing twelve months of adjusted EBITDA.
- Free Cash Flow % Revenue: Trailing twelve months of free cash flow divided by trailing twelve months of revenue.



Allscripts Non-GAAP Financial Measures

Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Allscripts excludes acquisition-related amortization expense from non-GAAP gross profit, non-GAAP operating income, and non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods because of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods.

Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. Allscripts excludes stock-based compensation expense from non-GAAP gross profit, non-GAAP operating income, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods.

Transaction and Other Costs. Transaction and other costs relate to certain legal proceedings and investigations, consulting, severance, incentive compensation and other charges incurred in connection with activities that are considered not reflective of our core business. Other costs also include non-cash impairment charges based on management's assessment of the likelihood of near-term recovery of the investments' value.

Allscripts excludes transaction and other costs, in whole or in part, from non-GAAP gross profit, non-GAAP operating income, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods.



Allscripts Non-GAAP Financial Measures

Asset Impairment Charges. Asset impairment charges reflect non-cash charges related to the write-offs of deferred costs related to our private cloud hosting operations.

Management also believes that non-GAAP gross profit, income from operations, effective income tax rate, net income, diluted earnings per share, Adjusted EBITDA, Adjusted EBITDA margin and free cash flow provide useful supplemental information to management and investors regarding the underlying performance of Allscripts business operations. Acquisition accounting adjustments, transaction, and other costs recorded in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein.

Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP gross profit, operating income, net income, diluted earnings per share, Adjusted EBITDA and/or Adjusted EBITDA margin to measure achievement under Allscripts stock and cash incentive compensation plans. Note, however, that non-GAAP gross profit, operating income, net income, diluted earnings per share, Adjusted EBITDA and Adjusted EBITDA margin are performance measures only, and they do not provide any measure of cash flow or liquidity. Allscripts considers free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business after capital expenditures and capitalized software costs. Free cash flow provides management and investors a valuable measure to determine the quantity of capital generated that can be deployed to create additional shareholder value by a variety of means. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the definitions and reconciliations of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

